# OnCo record nct07554521 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07554521/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07554521", "NCT07554521" ;
  schema:name "A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States"@en ;
  schema:description "A phase 2 trial of Tislelizumab, Capecitabine, Fluorouracil (5-FU) and Oxaliplatin in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by BeOne Medicines, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07554521/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07554521> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2026-04-30" ;
  onco:cancers <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/esophageal/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/oxaliplatin/> ;
  onco:companies <https://onco.cc/companies/beone/> .